The FDA moved to address litigation risk while reworking its handling of pharma rejection letters, with agency postings indicating a pause followed by a partial restart. Separately, the FDA also published a run of new complete response letters (CRLs) to drugmakers, signaling that enforcement and manufacturing scrutiny remain active. For sponsors, the immediate takeaway is that application outcomes continue to hinge on compliance-level details, including manufacturing and data completeness, even as the agency adjusts transparency mechanics around CRLs. The operational impact is likely to show up in timelines for resubmissions and downstream investor guidance. The policy implications are material for biotech planning: while the FDA’s CRL disclosure approach is in flux, manufacturing and quality expectations do not appear to be changing in parallel.